Recurrent Melanoma Active Not Recruiting Phase 2 Trials for DB06186 (Ipilimumab)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02203604High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By SurgeryTreatment
NCT01950390Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryTreatment
NCT01134614Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by SurgeryTreatment
NCT02158520Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by SurgeryTreatment
NCT01708941Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryTreatment
NCT01970527Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV MelanomaTreatment
NCT02107755Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic MelanomaTreatment